This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Trends in Psoriasis Research: Biologics, Biosimilars and New Therapies Recent innovations in biologics and biosimilars have transformed psoriasis care. Meanwhile, Innovent Biologics recently saw its New Drug Application (NDA) for picankibart, an IL-23p19 inhibitor, accepted by the Chinese National Medical Products Administration (NMPA).
Sanofi has signed an agreement with the Queensland Government in Australia to establish a $190m (A$280m) research facility in Brisbane. The hub will connect Queensland scientists with the teams at Sanofi’s mRNA Centre of Excellence in the US and France, putting them at the front of international vaccine development and biomedical research.
While several therapeutics are available for treating symptoms associated with epilepsy, researchers and patients have strongly called out the need for more holistic treatments that would address the condition as a whole. Meanwhile, others are researching the link between gene variation and different responses to treatments.
Researchers from Johns Hopkins University School of Medicine have revealed new findings about a key pathological protein associated with Parkinson’s disease (PD), which could lead to new treatments. However, its relation to dopaminergic neuron death is unclear.
In 2025, new initial public offerings (IPOs) are emerging across packaged foods, alternative proteins and tech-enabled food solutions, signaling that scientific investment is becoming a key competitive differentiator. Below is a look at recent beverage and food IPOs of 2025. In February 2025, the company raised approximately $1.14
Gilead Sciences has exercised its option to exclusively license the investigational targeted protein degrader development candidate, NX‑0479, from clinical-stage biopharmaceutical company Nurix Therapeutics. Additionally, Nurix will receive up to low double-digit tiered royalties on the net sales of the product.
Japan-based Astellas Pharma has entered a partnership with Cullgen to discover and develop multiple targeted protein degraders through the latter’s proprietary uSMITE targeted protein degradation platform, in a deal potentially worth $1.9bn. This method can target enzymes, transcription factors, scaffold proteins and more.
A new publication released today in The EMBO Journal identified a key protein in the molecular mechanism triggering neurogenesis in the hippocampus. They found that tight regulation of Yap1 activity is essential as dysregulation can cause tissue disruption seen in the early stages of brain cancer.
The companies will use the natural product discovery capabilities of Ginkgo Bioworks to expedite the discovery and development of new therapeutic molecules to address diseases with high unmet patient needs.
A collaboration including researchers from Kobe University, University of Tokyo and Tohoku University has successfully identified and disrupted genes in the yeast Pichia pastoris (1) in order to increase its secretory production of useful proteins (2).
California-based startup Air Protein developed an alt meat called Air Meat, which is made using microbes that turn recycled carbon dioxide (CO2) into protein. Described by the company as “the meat of tomorrow,” Air Meat was designed to replicate the flavor and texture of real meat products like chicken, pork, steak and seafood.
BMS researchers on the mission will study the crystallization of an assortment of their biologics medicines in microgravity. By growing high quality crystal structures of protein-based therapeutics under microgravity, researchers can gain better insights into their complex structures and stability.
API peptides and proteins-based drugs have gained much attention in the past decade. Peptide API products have become popular due to their proven pharmacological value and favourable safety profiles. Discover the top API protein and peptide companies in contract marketing. Technologies in the delivery of peptides and proteins.
In May 2022, they signed a research partnership and exclusive option licence agreement for the development of antibodies to reduce tumour microenvironment-mediated immunosuppression. The companies signed another research collaboration agreement for multi-target antibody discovery in January 2023.
Medicines that are based on mRNAs and proteins—particularly vaccines and antibodies—are time-intensive and costly to make. The challenge is in producing the necessary mRNAs and proteins in large enough amounts at low cost.
Biotheryx and Incyte have signed an agreement for identifying and developing targeted protein degraders for historically undruggable oncology targets. Incyte will pay a $7m technology access fee to Biotheryx for the initial target and potential research, and development funding of up to an additional $6m for costs related to the partnership.
Rilzabrutinib joins a wave of innovative ITP therapies , including thrombopoietin-receptor agonists like eltrombopag and romiplostim, which boost platelet production. Rilzabrutinib works by targeting BTK, a protein involved in immune cell communication.
But several researchers and experts have brought to light some food safety concerns of plant-based meat, and why it must be treated differently than that of animal protein. Traditional meat production faces a wide array of safety concerns, from slaughterhouse sanitation to foodborne illnesses and much more. Ultra-Processed.
EverGrain Ingredients, a barley protein and fiber solutions company, recently received certification from the Upcycled Food Association (UFA) for its entire portfolio of products. The brand saw a unique opportunity to extract the excess barley to meet the global demand for sustainable, plant-based products. Barley Milk.
This is the latest episode of the free DDW narrated podcast, titled Where are the global breakthroughs, opportunities and developments in cancer research?, I spoke with him about how AstraZeneca is innovating to displace chemotherapy and research areas of significance. appeared first on Drug Discovery World (DDW).
Oncology products monopolise the list of best-selling drugs. Several oncology products now have “blockbuster” status where sales exceed $1 billion annually. This is relevant for clinical trials as more regulators require evidence of efficacy in comparison to the standard of care, which is likely to be one of the blockbuster products.
Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs). The post Ono Pharmaceutical enters research deal with Monash University appeared first on Pharmaceutical Technology.
The research by the Future Sustainable Food Systems research group at the University of Helsinki together with VTT Technical Research Centre of Finland shows that fungus-produced ovalbumin could have the potential to mitigate part of the environmental burden associated with chicken egg white powder.
First, a novel approach was used that didn’t require traditional vaccine production in cell cultures or eggs. Once introduced into the human body, the protein-making machinery uses this genetic material in our cells to churn out the coronavirus “spike protein,” triggering an immune response.
Drug discovery company Veneno Technologies has signed a joint research agreement with Japanese pharmaceutical company Astellas Pharma. Veneno will carry out a programme to generate functional peptides (DRPs) for G protein-coupled receptors (GPCRs), which will be targeted by Astellas.
In an email to Pharmaceutical Technology , an NHSBT spokesperson said the centre will “support early phase clinical trials and preclinical work, providing a route to eventual commercial scale production”. The NHSBT representative explained that a lack of manufacturing spaces led to delays in production slots for many gene therapy developers.
This process is regulated by a family of signaling proteins called sirtuins. A recent study by researchers from Kumamoto University reveals the mechanism through which the protein sirtuin 7 suppresses thermogenesis in mice. Mammals convert the energy stored in adipose (fat) tissue into heat via a process known as thermogenesis.
Ever After Foods’ unique breakthrough lies in its proprietary bioreactor setup, which has the potential to tackle the central challenge of escalating cultivated meat production. Recent research suggests that cultivated meat is more sustainable than traditional animal products, especially when coupled with renewable energy use.
The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. Definition of Biologic Products. These products can be derived from humans, animals, or microorganisms with biotechnology.
As per the prior and expanded agreements, ProQR is entitled to get research, development and commercialisation milestone payments totalling up to nearly $3.75bn, apart from tiered royalty payments on sales of products. The company can also choose to grant ProQR access to its delivery technology for the fully owned pipeline.
Medical charity Alzheimer’s Research UK has teamed up with artificial intelligence specialist Exscientia to find new drug treatments for the devastating neurodegenerative disease. . It reckons its use of AI and machine learning can trim years off the current 12- to 15-year cycle from early research to marketed product.
Researchers at the CNIO (Spanish National Cancer Research Center) have discovered that one of the causes for the rare tumor pheochromocytoma-paraganglioma is the interruption of a very specific step in the production of some proteins, called succinylation.
Amazon’s Launchpad program empowers and accelerates start-up businesses that will sell their products amazon.com. Until now, no plant-based products could match what the sports nutrition category was doing. ” Related: RXBAR Introduces its First Plant-Based Protein Bar. Additionally, GNC placed an initial $3.4
Forma focuses on researching, developing and marketing new therapies for patients with sickle cell disease (SCD), rare hematologic diseases and cancers. A group of ailments, haemoglobinopathies is associated with an irregular production or structure of the haemoglobin protein in the red blood cells.
binding antibody, a cell-surface protein which is greatly expressed in ovarian cancer, as well as the maytansinoid payload DM4. In February, the company signed a licencing agreement under which Eli Lilly and Company obtained exclusive rights to conduct the research, development and marketing of ADCs. The ADC comprises an FR?-binding
Dual-function fusion proteins represent a cutting-edge approach in biopharmaceutical research, offering a promising avenue for the development of novel therapeutics in the treatment of complex diseases such as cancer and autoimmune disorders. My initial exposure to medicine came through bench research.
The introduction of new first-in-class biological therapies will further increase therapy options for SLE and LN patients, and it remains to be seen if any of these products will have superior efficacy and safety profiles to currently available Benlysta, Rituxan, Lupkynis and Saphnelo.
The results are reported in an article published in the journal Probiotics and Antimicrobial Proteins. The authors are researchers at the University of São Paulo (USP) and the Federal University of Minas Gerais (UFMG). The yeast strain used in the study was Saccharomyces cerevisiae UFMG A-905.
Now, thanks to a study funded by the National Institutes of Health Intramural Research Program, scientists have discovered that ?-synuclein, synuclein, a protein involved in the formation of amyloid deposits in the brain characteristic of Parkinson’s disease and other neurodegenerative disorders, is also implicated in melanoma.
A recent report has found that R&D productivity rose vertiginously during 2021, but how much of this was organic and how much can be attributed to the pandemic? The pandemic also saw a reduction in the overall development cycle of a product, which has been growing in recent years. In 2020, the development cycle averaged 7.14
Since HIV integrates with the DNA, eliminating the virus from the body is very difficult, explains David Montefiori, PhD, director of the Laboratory for AIDS Vaccine Research and Development at Duke University in Durham, North Carolina. But others in the research space are now testing out other concepts that have been largely theoretical.
The two-dose protein-based, adjuvanted vaccine has been authorized for use in adults 18 years of age and older for the prevention of COVID-19 caused by SARS-CoV-2. Nevertheless, 77 percent of those polled said that even if a protein-based COVID shot were authorized in the US, they still would not get it.
However, according to new research by the University of Cincinnati, amyloid plaques may not be the major cause of AD as previously thought—so are they the best target? ABPP Inhibitors lead by a significant margin, having 38% more drugs in development than the next leading MoA, microtubule-associated protein tau (MAPT) inhibitors.
In a new study by researchers from Mass General Brigham's founding members, Brigham and Women's Hospital and Massachusetts General Hospital, a team extensively investigated the immune response of 16 adolescents and young adults who developed myocarditis after receipt of the COVID mRNA vaccine. Their results are published in Circulation.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content